A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections

Kohei Hara; Shigeru Kohno; Hironobu Koga; Akira Saito; Mitsuhide Ohmichi; Yohmei Hiraga; Kazuo Takebe; Tsukasa Yoshida; Toshiharu Ito; Akira Watanabe; Kazuo Sato; Kikuo Onuma; Masataka Katsu; Akira Ohishi; Junzaburo Kabe; Hitoshi Arioka; Noriko Nakajima; Atsuhito Yoshizawa; Koichiro Nakata; Yoshitaka Nakamori; Tatsuo Nakatani; Kohji Narui; Eiyasu Tsuboi; Kaoru Shimada; Hajime Goto; Takashi Inamatsu; Makoto Kodaira; Yoshishige Masuda; Yasuyuki Sano; Ken Koshino; Yasuo Arai; Jingoro Shimadaand; Masaki Yoshida; Hiroichi Tanimoto; Hiroyuki Kobayashi; Hisashi Inoue; Masaru Koyama; Shigeki Odagiri; Masanori Matsumura; Kaneo Suzuki; Yasuhiko Ashikari; Akira Shoji; Masaaki Arakawa; Kouichi Wada; Takashi Kawashima; Masanaga Takatoh; Shigeyuki Hoshino; Fumihide Iwata; Naoki Osaki; Yoshinori Shimazu; Osamu Sekine; Yasutoshi Suzuki; Nobuki Aoki; Saburo Izumi; Susumu Kishimoto; Tomiya Masuno; Seiji Hayashi; Eiro Tsubura; Masaru Nakagawa; Tsuyoshi Igarashi; Kiyoshi Komuta; Mitsunori Sakatani; Mitsumasa Ogawara; Norio Ochi; Norio Itakura; Masami Ito; Naoyoshi Kojiro; Toshiyuki Ikeda; Takahiko Yoshimoto; Hideki Hara; Toru Kumagai; Fumio Miki; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Rinzo Soejima; Masaru Sumi; Toshiharu Matsushima; Makoto Kimura; Takao Sasaki; Yukio Matsumoto; Yuji Sugimoto; Michio Yamakido; Kenji Hasegawa; Kenichiro Sadamoto; Masao Kuwabara; Yukio Nishimoto; Jitsuo Yanagida; Masato Yukutake; Yukikazu Awaya; Osamu Kurimura; Hideo Sasaki; Akimasa Oune; Hisakazu Muranishi; Masayuki Miyazaki; Kotaro Oizumi; Yoichiro Ichikawa; Hisato Tokunaga; Masaru Nasu; Keizo Matsumoto; Atsushi Takahashi; Hirofumi Tanaka; Mikio Taguchi; Harumi Shishido; Hideaki Nagai; Koji Sato; Atsuyuki Kurashima; Kiyoshi Shima; Shinobu Takenaka; Atsushi Saito; Yuei Irabu; Nobuchika Kusano; Moriaki Wakuta; Nobuya Ogawa; Keizo Yamaguchi; Mitsuo Kaku; Kazuyuki Sugawara

doi:10.11250/chemotherapy1953.41.104

A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections

Kohei Hara, Shigeru Kohno, Hironobu Koga, Akira Saito, Mitsuhide Ohmichi, Yohmei Hiraga, Kazuo Takebe, Tsukasa Yoshida, Toshiharu Ito, Akira Watanabe, Kazuo Sato, Kikuo Onuma, Masataka Katsu, Akira Ohishi, Junzaburo Kabe, Hitoshi Arioka, Noriko Nakajima, Atsuhito Yoshizawa, Koichiro Nakata, Yoshitaka NakamoriTatsuo Nakatani, Kohji Narui, Eiyasu Tsuboi, Kaoru Shimada, Hajime Goto, Takashi Inamatsu, Makoto Kodaira, Yoshishige Masuda, Yasuyuki Sano, Ken Koshino, Yasuo Arai, Jingoro Shimadaand, Masaki Yoshida, Hiroichi Tanimoto, Hiroyuki Kobayashi, Hisashi Inoue, Masaru Koyama, Shigeki Odagiri, Masanori Matsumura, Kaneo Suzuki, Yasuhiko Ashikari, Akira Shoji, Masaaki Arakawa, Kouichi Wada, Takashi Kawashima, Masanaga Takatoh, Shigeyuki Hoshino, Fumihide Iwata, Naoki Osaki, Yoshinori Shimazu, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Saburo Izumi, Susumu Kishimoto, Tomiya Masuno, Seiji Hayashi, Eiro Tsubura, Masaru Nakagawa, Tsuyoshi Igarashi, Kiyoshi Komuta, Mitsunori Sakatani, Mitsumasa Ogawara, Norio Ochi, Norio Itakura, Masami Ito, Naoyoshi Kojiro, Toshiyuki Ikeda, Takahiko Yoshimoto, Hideki Hara, Toru Kumagai, Fumio Miki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Masaru Sumi, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Michio Yamakido, Kenji Hasegawa, Kenichiro Sadamoto, Masao Kuwabara, Yukio Nishimoto, Jitsuo Yanagida, Masato Yukutake, Yukikazu Awaya, Osamu Kurimura, Hideo Sasaki, Akimasa Oune, Hisakazu Muranishi, Masayuki Miyazaki, Kotaro Oizumi, Yoichiro Ichikawa, Hisato Tokunaga, Masaru Nasu, Keizo Matsumoto, Atsushi Takahashi, Hirofumi Tanaka, Mikio Taguchi, Harumi Shishido, Hideaki Nagai, Koji Sato, Atsuyuki Kurashima, Kiyoshi Shima, Shinobu Takenaka, Atsushi Saito, Yuei Irabu, Nobuchika Kusano, Moriaki Wakuta, Nobuya Ogawa, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ²-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.

Original language	English
Pages (from-to)	104-127
Number of pages	24
Journal	CHEMOTHERAPY
Volume	41
Issue number	1
DOIs	https://doi.org/10.11250/chemotherapy1953.41.104
Publication status	Published - 1993
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.41.104

Cite this

Hara, K., Kohno, S., Koga, H., Saito, A., Ohmichi, M., Hiraga, Y., Takebe, K., Yoshida, T., Ito, T., Watanabe, A., Sato, K., Onuma, K., Katsu, M., Ohishi, A., Kabe, J., Arioka, H., Nakajima, N., Yoshizawa, A., Nakata, K., ... Sugawara, K. (1993). A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections. CHEMOTHERAPY, 41(1), 104-127. https://doi.org/10.11250/chemotherapy1953.41.104

Hara, K, Kohno, S, Koga, H, Saito, A, Ohmichi, M, Hiraga, Y, Takebe, K, Yoshida, T, Ito, T, Watanabe, A, Sato, K, Onuma, K, Katsu, M, Ohishi, A, Kabe, J, Arioka, H, Nakajima, N, Yoshizawa, A, Nakata, K, Nakamori, Y, Nakatani, T, Narui, K, Tsuboi, E, Shimada, K, Goto, H, Inamatsu, T, Kodaira, M, Masuda, Y, Sano, Y, Koshino, K, Arai, Y, Shimadaand, J, Yoshida, M, Tanimoto, H, Kobayashi, H, Inoue, H, Koyama, M, Odagiri, S, Matsumura, M, Suzuki, K, Ashikari, Y, Shoji, A, Arakawa, M, Wada, K, Kawashima, T, Takatoh, M, Hoshino, S, Iwata, F, Osaki, N, Shimazu, Y, Sekine, O, Suzuki, Y, Aoki, N, Izumi, S, Kishimoto, S, Masuno, T, Hayashi, S, Tsubura, E, Nakagawa, M, Igarashi, T, Komuta, K, Sakatani, M, Ogawara, M, Ochi, N, Itakura, N, Ito, M, Kojiro, N, Ikeda, T, Yoshimoto, T, Hara, H, Kumagai, T, Miki, F, Narita, N, Sawaki, M, Mikasa, K, Soejima, R, Sumi, M, Matsushima, T, Kimura, M, Sasaki, T, Matsumoto, Y, Sugimoto, Y, Yamakido, M, Hasegawa, K, Sadamoto, K, Kuwabara, M, Nishimoto, Y, Yanagida, J, Yukutake, M, Awaya, Y, Kurimura, O, Sasaki, H, Oune, A, Muranishi, H, Miyazaki, M, Oizumi, K, Ichikawa, Y, Tokunaga, H, Nasu, M, Matsumoto, K, Takahashi, A, Tanaka, H, Taguchi, M, Shishido, H, Nagai, H, Sato, K, Kurashima, A, Shima, K, Takenaka, S, Saito, A, Irabu, Y, Kusano, N, Wakuta, M, Ogawa, N, Yamaguchi, K, Kaku, M & Sugawara, K 1993, 'A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections', CHEMOTHERAPY, vol. 41, no. 1, pp. 104-127. https://doi.org/10.11250/chemotherapy1953.41.104

@article{63fd90e6688748e6a77103c4508552e1,

title = "A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections",

abstract = "We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.",

author = "Kohei Hara and Shigeru Kohno and Hironobu Koga and Akira Saito and Mitsuhide Ohmichi and Yohmei Hiraga and Kazuo Takebe and Tsukasa Yoshida and Toshiharu Ito and Akira Watanabe and Kazuo Sato and Kikuo Onuma and Masataka Katsu and Akira Ohishi and Junzaburo Kabe and Hitoshi Arioka and Noriko Nakajima and Atsuhito Yoshizawa and Koichiro Nakata and Yoshitaka Nakamori and Tatsuo Nakatani and Kohji Narui and Eiyasu Tsuboi and Kaoru Shimada and Hajime Goto and Takashi Inamatsu and Makoto Kodaira and Yoshishige Masuda and Yasuyuki Sano and Ken Koshino and Yasuo Arai and Jingoro Shimadaand and Masaki Yoshida and Hiroichi Tanimoto and Hiroyuki Kobayashi and Hisashi Inoue and Masaru Koyama and Shigeki Odagiri and Masanori Matsumura and Kaneo Suzuki and Yasuhiko Ashikari and Akira Shoji and Masaaki Arakawa and Kouichi Wada and Takashi Kawashima and Masanaga Takatoh and Shigeyuki Hoshino and Fumihide Iwata and Naoki Osaki and Yoshinori Shimazu and Osamu Sekine and Yasutoshi Suzuki and Nobuki Aoki and Saburo Izumi and Susumu Kishimoto and Tomiya Masuno and Seiji Hayashi and Eiro Tsubura and Masaru Nakagawa and Tsuyoshi Igarashi and Kiyoshi Komuta and Mitsunori Sakatani and Mitsumasa Ogawara and Norio Ochi and Norio Itakura and Masami Ito and Naoyoshi Kojiro and Toshiyuki Ikeda and Takahiko Yoshimoto and Hideki Hara and Toru Kumagai and Fumio Miki and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Rinzo Soejima and Masaru Sumi and Toshiharu Matsushima and Makoto Kimura and Takao Sasaki and Yukio Matsumoto and Yuji Sugimoto and Michio Yamakido and Kenji Hasegawa and Kenichiro Sadamoto and Masao Kuwabara and Yukio Nishimoto and Jitsuo Yanagida and Masato Yukutake and Yukikazu Awaya and Osamu Kurimura and Hideo Sasaki and Akimasa Oune and Hisakazu Muranishi and Masayuki Miyazaki and Kotaro Oizumi and Yoichiro Ichikawa and Hisato Tokunaga and Masaru Nasu and Keizo Matsumoto and Atsushi Takahashi and Hirofumi Tanaka and Mikio Taguchi and Harumi Shishido and Hideaki Nagai and Koji Sato and Atsuyuki Kurashima and Kiyoshi Shima and Shinobu Takenaka and Atsushi Saito and Yuei Irabu and Nobuchika Kusano and Moriaki Wakuta and Nobuya Ogawa and Keizo Yamaguchi and Mitsuo Kaku and Kazuyuki Sugawara",

year = "1993",

doi = "10.11250/chemotherapy1953.41.104",

language = "English",

volume = "41",

pages = "104--127",

journal = "Chemotherapy",

issn = "0009-3165",

number = "1",

}

TY - JOUR

T1 - A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Koga, Hironobu

AU - Saito, Akira

AU - Ohmichi, Mitsuhide

AU - Hiraga, Yohmei

AU - Takebe, Kazuo

AU - Yoshida, Tsukasa

AU - Ito, Toshiharu

AU - Watanabe, Akira

AU - Sato, Kazuo

AU - Onuma, Kikuo

AU - Katsu, Masataka

AU - Ohishi, Akira

AU - Kabe, Junzaburo

AU - Arioka, Hitoshi

AU - Nakajima, Noriko

AU - Yoshizawa, Atsuhito

AU - Nakata, Koichiro

AU - Nakamori, Yoshitaka

AU - Nakatani, Tatsuo

AU - Narui, Kohji

AU - Tsuboi, Eiyasu

AU - Shimada, Kaoru

AU - Goto, Hajime

AU - Inamatsu, Takashi

AU - Kodaira, Makoto

AU - Masuda, Yoshishige

AU - Sano, Yasuyuki

AU - Koshino, Ken

AU - Arai, Yasuo

AU - Shimadaand, Jingoro

AU - Yoshida, Masaki

AU - Tanimoto, Hiroichi

AU - Kobayashi, Hiroyuki

AU - Inoue, Hisashi

AU - Koyama, Masaru

AU - Odagiri, Shigeki

AU - Matsumura, Masanori

AU - Suzuki, Kaneo

AU - Ashikari, Yasuhiko

AU - Shoji, Akira

AU - Arakawa, Masaaki

AU - Wada, Kouichi

AU - Kawashima, Takashi

AU - Takatoh, Masanaga

AU - Hoshino, Shigeyuki

AU - Iwata, Fumihide

AU - Osaki, Naoki

AU - Shimazu, Yoshinori

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Aoki, Nobuki

AU - Izumi, Saburo

AU - Kishimoto, Susumu

AU - Masuno, Tomiya

AU - Hayashi, Seiji

AU - Tsubura, Eiro

AU - Nakagawa, Masaru

AU - Igarashi, Tsuyoshi

AU - Komuta, Kiyoshi

AU - Sakatani, Mitsunori

AU - Ogawara, Mitsumasa

AU - Ochi, Norio

AU - Itakura, Norio

AU - Ito, Masami

AU - Kojiro, Naoyoshi

AU - Ikeda, Toshiyuki

AU - Yoshimoto, Takahiko

AU - Hara, Hideki

AU - Kumagai, Toru

AU - Miki, Fumio

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Soejima, Rinzo

AU - Sumi, Masaru

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sugimoto, Yuji

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Sadamoto, Kenichiro

AU - Kuwabara, Masao

AU - Nishimoto, Yukio

AU - Yanagida, Jitsuo

AU - Yukutake, Masato

AU - Awaya, Yukikazu

AU - Kurimura, Osamu

AU - Sasaki, Hideo

AU - Oune, Akimasa

AU - Muranishi, Hisakazu

AU - Miyazaki, Masayuki

AU - Oizumi, Kotaro

AU - Ichikawa, Yoichiro

AU - Tokunaga, Hisato

AU - Nasu, Masaru

AU - Matsumoto, Keizo

AU - Takahashi, Atsushi

AU - Tanaka, Hirofumi

AU - Taguchi, Mikio

AU - Shishido, Harumi

AU - Nagai, Hideaki

AU - Sato, Koji

AU - Kurashima, Atsuyuki

AU - Shima, Kiyoshi

AU - Takenaka, Shinobu

AU - Saito, Atsushi

AU - Irabu, Yuei

AU - Kusano, Nobuchika

AU - Wakuta, Moriaki

AU - Ogawa, Nobuya

AU - Yamaguchi, Keizo

AU - Kaku, Mitsuo

AU - Sugawara, Kazuyuki

PY - 1993

Y1 - 1993

N2 - We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.

AB - We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.

UR - http://www.scopus.com/inward/record.url?scp=0027462741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027462741&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.41.104

DO - 10.11250/chemotherapy1953.41.104

M3 - Article

AN - SCOPUS:0027462741

VL - 41

SP - 104

EP - 127

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - 1

ER -

A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this